LL-37 — 5mg Research Compound

LL-37 (5mg) — Research Compound

LL-37 is a multifunctional antimicrobial peptide belonging to the cathelicidin family, primarily expressed by immune cells and epithelial tissues. Beyond its direct interaction with bacterial cell membranes, LL-37 is studied for its role in wound healing, angiogenesis, and immune cell recruitment. Research focuses on its ability to modulate the inflammatory response and its potential to act as a signalling molecule in structural tissue repair pathways.

Findings from early-stage clinical trials have reported:

• Accelerated rates of re-epithelialisation in chronic wound models observed in experimental studies
  
• Broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria reported in-vitro
  
• Increased recruitment of leukocytes and mesenchymal stem cells to injury sites noted in-vivo
  
• Observed modulation of pro-inflammatory cytokine levels reported in experimental skin research
  

Researchers study LL-37 to investigate its potential in overcoming antibiotic resistance and its utility in regenerative medicine. By examining its interaction with Formyl Peptide Receptor 2 (FPR2), it serves as a specialised tool for understanding how innate immunity influences structural tissue recovery. This makes it a significant compound for research into complex dermal recovery and the biological mechanisms of the first-line immune defence.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use